Haya Therapeutics
Founded Year
2019Stage
Grant | AliveTotal Raised
$28.54MLast Raised
$3.3M | 1 yr agoAbout Haya Therapeutics
HAYA Therapeutics is a precision therapeutics company that discovers and develops tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long, non-coding RNAs (lncRNAs) within the “dark matter” of the human genome – key tissue and cell-specific drivers of fibrosis and other disease processes – to identify targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA’s lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown in preclinical testing the ability to halt and potentially reverse the fibrotic processes underlying heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers. Haya Therapeutics was founded in 2019 and is based in Lausanne, Switzerland.
Compete with Haya Therapeutics?
Ensure that your company and products are accurately represented on our platform.
Haya Therapeutics's Products & Differentiators
DiscoverHAYA™️
Our proprietary drug discovery engine enables us to discover and generate a pipeline of lncRNA targeting anti-fibrotic candidates for many tissues including lung, kidney, liver and the tumor microenvironment. These lead targets have the potential for significantly greater efficacy, safety and accessibility than existing treatments
Expert Collections containing Haya Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Haya Therapeutics is included in 2 Expert Collections, including Biopharma Tech.
Biopharma Tech
5,241 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Omics
1,267 items
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Latest Haya Therapeutics News
Feb 17, 2023
LAUSANNE, Switzerland & SAN DIEGO–(BUSINESS WIRE)–HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Ahmad Masri, M.D., M.S. and Cedric Feschotte, Ph.D. are joining HAYA’s advisory boards. The post HAYA Therapeutics Adds World-Leading Cardiologist and Dark Genome Pioneer to Advisory Boards appeared first on Broadview Ventures.
Haya Therapeutics Frequently Asked Questions (FAQ)
When was Haya Therapeutics founded?
Haya Therapeutics was founded in 2019.
Where is Haya Therapeutics's headquarters?
Haya Therapeutics's headquarters is located at Route de la Corniche 6, Lausanne.
What is Haya Therapeutics's latest funding round?
Haya Therapeutics's latest funding round is Grant.
How much did Haya Therapeutics raise?
Haya Therapeutics raised a total of $28.54M.
Who are the investors of Haya Therapeutics?
Investors of Haya Therapeutics include Innosuisse, Broadview Ventures, Viva BioInnovator, 4see Ventures, Apollo Health Ventures and 8 more.
What products does Haya Therapeutics offer?
Haya Therapeutics's products include DiscoverHAYA™️.
Compare Haya Therapeutics to Competitors
HAYA Therapeutics is a precision therapeutics company that discovers and develops tissue- and cell-selective genomic medicines for fibrotic diseases and other serious health conditions associated with aging, including cancer. The company’s discovery engine focuses on long, non-coding RNAs (lncRNAs) within the “dark matter” of the human genome – key tissue and cell-specific drivers of fibrosis and other disease processes – to identify targets and drug candidates with the potential for greater efficacy and safety than existing treatments. HAYA’s lead therapeutic candidate is an antisense molecule targeting Wisper, a cardiac-enriched master driver of fibrosis, which has shown in preclinical testing the ability to halt and potentially reverse the fibrotic processes underlying heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the tissue-specific treatment of fibrotic diseases in other tissues, including lungs, kidney, liver, and the micro-environment of solid tumor cancers. Haya Therapeutics was founded in 2019 and is based in Lausanne, Switzerland.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.